Combined GLP-1 and Dual GIP/GLP-1 Receptor Agonists: American Diabetes Association Guidance

Temporary shortages of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have increased the marketing of compounded formulations.

• The use of GLP-1 receptor agonists and GIP/GLP-1 receptor agonists has significantly risen for type 2 diabetes and obesity treatment.
• Shortages of these medications have raised concerns about the safety and efficacy of compounded formulations that bypass regulatory standards.
• Even with improving availability of standard medications, compounded products remain widely advertised to individuals with diabetes and obesity.
• Guidance is necessary for healthcare professionals and patients to ensure safety and optimal care amidst these medication challenges.

Simplified